Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.
Clinical trial NCT07125079 · RECRUITING
Trial details
- NCT number
- NCT07125079
- Sponsor
- University of Pennsylvania
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-05-20
- Primary completion
- 2026-12-20
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.